Código QR (código de barras bidimensional)

Current status and future perspective on the management of metastatic castration-sensitive prostate cancer

Since 1941, the standard treatment for metastatic castration-sensitive prostate cancer (mCSPC) was androgen deprivation therapy (ADT) by surgical or medical castration with or without first-generation antiandrogen. However, the efficacy of ADT does not last in most cases. In the 2010s, de-intensific...

ver descrição completa

Na minha lista:
Principais autores: Leandro Blas, Masaki Shiota, Masatoshi Eto
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2022-01-01
coleção:Cancer Treatment and Research Communications
Assuntos:
Abiraterone
Androgen deprivation therapy
Docetaxel
Metastatic castration-sensitive prostate cancer
Radiotherapy
Radical prostatectomy
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S246829422200096X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados